How mRNA Technology Beyond COVID Is Transforming Medicine

mRNA technology proved itself with COVID-19 vaccines, but its potential extends far beyond. Moderna and BioNTech are developing mRNA vaccines for: influenza (phase 3 trials), RSV (approved), HIV (phase 1), malaria (preclinical), and personalized cancer vaccines (phase 2). The platform advantage is speed: mRNA vaccines can be designed and manufactured in weeks vs years for traditional approaches. Beyond vaccines, mRNA is being developed for: rare diseases (protein replacement therapy), autoimmune conditions (tolerance induction), and gene editing (delivering CRISPR components). The $100B+ mRNA therapeutics market could transform medicine as profoundly as antibiotics did in the 20th century.